Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

43.90 +1.11 (+2.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Definium Therapeutics, Inc. - Common Shares

News headline image
Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study ↗
Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Voyage, its Phase III study evaluating a single 100 mcg dose of DT120 ODT for generalized anxiety disorder, or GAD. The... 
Via MarketBeat
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Definium Therapeutics Q2 Earnings Call Highlights ↗
Definium Therapeutics (NASDAQ:DFTX) said it expects to report top-line results from its Phase III VOYAGE study of DT120 ODT in generalized anxiety disorder during the week of Aug. 10, following... 
Via MarketBeat
Topics Earnings
Definium Therapeutics (NASDAQ:DFTX) Slides After Q2 Loss Misses Estimates on Warrant Charge ↗
Via Chartmill
Definium Therapeutics (NASDAQ:DFTX) Misses EPS but Pipeline Progress Steals the Spotlight ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗
Via Chartmill
Which stocks are moving on Monday? ↗
Via Chartmill
Monday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program ↗
Definium Therapeutics (NASDAQ:DFTX) Chief Financial Officer Brandi Roberts said the company is preparing for several key clinical and regulatory milestones for DT-120, including anticipated Phase III... 
Via MarketBeat
News headline image
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing ↗
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions. 
Via The Motley Fool
News headline image
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish ↗
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Definium (DFTX) Q1 2026 Earnings Transcript ↗
Definium (DFTX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
These 3 Psychedelic Stocks Activated After Trump's Executive Order ↗
Via MarketBeat
Topics Government
News headline image
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
Trump is easing approval for psychedelic treatments for mental disorders. 
Via The Motley Fool
Topics Government
News headline image
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗
This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Definium (DFTX) Q4 2025 Earnings Call Transcript ↗
Definium (DFTX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.